Treatment of Relapsed/Refractory Myeloma (excluding T-cell redirection therapy)
Real-world Effectiveness of Ixazomib, Lenalidomide, and Dexamethasone (IRd) in Asian Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
Youngil Koh, MD, PhD (he/him/his)
Associate Professor
Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea
Seoul, Republic of Korea
South Korea (n=69) | Malaysia (n=27) | Thailand (n=8) | Total (N=104) | |
Primary outcomes | ||||
TTNT, months, median (95% CI) | 31.6 (18.2, NR) | 27.4 (8.7, 41.8) | NR (6.2, NR) | 32.1 (22.5, NR) |
ORR, n (%) [95% CI] | 55 (79.7) [68.3, 88.4] | 13 (48.2) [28.7, 68.1] | 7 (87.5) [47.4, 99.7] | 75 (72.1) [62.5, 80.5] |
Stringent complete response | 1 (1.5) [0.04, 7.8] | 0 [0, 12.8] | 0 [0, 36.9] | 1 (1) [0.02, 5.2] |
Complete response | 18 (26.1) [16.3, 38.1] | 5 (18.5) [6.3, 38.1] | 4 (50.0) [15.7, 84.3] | 27 (26.0) [17.9, 35.5] |
Very good partial response | 14 (20.3) [11.6, 31.7] | 2 (7.4) [0.9, 24.3] | 3 (37.5) [8.5, 75.5] | 19 (18.3) [11.4, 27.1] |
Partial response | 22 (31.9) [21.2, 44.2] | 6 (22.2) [8.6, 42.3] | 0 [0, 36.9] | 28 (26.9) [18.7, 36.5] |
Secondary outcomes, months, median (95% CI) | ||||
Duration of treatment | 14.3 (10.4, 25.4) | 13.2 (4.5, 27.1) | 47.3 (5.6, 50.5) | 14.8 (11.3, 23.0) |
OS | NR (NR, NR) | NR (33.0, NR) | NR (20.8, NR) | NR (58.0, NR) |
PFS | 27.7 (22.5, NR) | 16.9 (7.0, NR) | NR (1.7, NR) | 27.7 (19.5, NR) |